Transparency Submission

Ward, Suzanne
suzanne.ward@btgsp.com
6155009661
08/07/2024
Company: BTG
Guideline: B-Cell Lymphomas
Panel: B-Cell Lymphomas Panel
Algorithm Page Number: Change requested to the following pages: MANT-A 3 of 5, BCEL-A 2 of 2, BCEL-B 1 of 3, BCEL-C 4 of 6, HGBL-1, BURK-A 1 of 3, HIVLYM-A 1 of 2, PTLD-A
Specific Change Requested: We request that a footnote be added to the Systemic Therapy sections of the B-Cell Lymphomas Guidelines, specifically in sections where high-dose methotrexate is recommended. Our request is to add a footnote with the following statement “During systemic high-dose methotrexate treatment, consider glucarpidase for delayed methotrexate clearance due to renal impairment.”
FDA Clearance: Glucarpidase is FDA approved for delayed methotrexate clearance due to renal impairment.
Rationale for Requested Change: Although glucarpidase is recommended in the Supportive Care section of the NCCN guideline for B-Cell Lymphoma, in order for glucarpidase to be included in the NCCN Drugs & Biologics Compendium, an important authoritative reference for oncology coverage policy that impacts patient access to appropriate therapy, including critical antidotes such as glucarpidase, this change of adding a footnote to the Systemic Therapy section of the guideline is required.
Citation of Literature
Ramsey LB, Balis FM, O'Brien MM, et al. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist 2018;23(1):52-61.
3025 Chemical Road, Suite 100, Plymouth Meeting, PA 19462
Phone: 215-690-0300
Fax: 215-690-0280
Copyright © National Comprehensive Cancer Network, All Rights Reserved.

No portion of this Site or any NCCN Content may be copied, transferred, reproduced, modified, or otherwise used for any purpose without NCCN’s express written permission.
See Legal Notices Section for additional notices and terms governing your use of this Site.